All News

With so much variation, why force local affiliates to use the global agency?This is a battle seldom worth the fight.

An ideal partner is one that will work with manufacturers on a variable cost basis, providing the ability to scale resources up and down as new products are introduced and marketing and sales needs change.

To assume that growing a marketing presence in emerging markets automatically requires a global agency network is a flawed assumption.

Sure, there might be a few key audiences whose view of your reputation is critical, but targeting them is fairly simple and often inexpensive. More times than not, it's better to keep your head down than raise the banner and lead the field.

Independence equals creativity, and solutions

Strategy-listening, seeing, thinking-all need to be done locally.

The monolithic dictates out of marketing and agency headquarters in New York and London-and the way they are forced on local marketing efforts-work to undermine adoption at the local level

In China people view expenditures on pharmaceuticals as a "cost" rather than a "purchase"

The pharma industry has only recently seen the kinds of price pressures that the retail industry has operated under for decades.

Emerging Pharma Leaders

The public-interest charity takes on pharma-influenced medicing and drug-resistant bacteria.

Pharma companies can maximize partnership benefits with social media.

Innovation in industry has always required a strong internal champion; the danger is a process led by the risk-adverse and externally-driven stakeholder consensus called "death by faint praise." Is this really what we mean by "bold partnerships?"

May 24, 2010.

In the wake of megamergers and healthcare reform, Pfizer and Merck both produce fairly positive first quarter results

One Pill Makes You Better?

Cash-rich Big Pharmas are hedging their bets to cover both segments under the rubric of "diversification." If it sticks to the wall, then buy it.

Marketers must focus on getting busy women the help they need in making critical decisions about their healthcare.

A new Cegedim Dendrite study shows just how ill-equipped pharmaceutical companies are to deal with spending disclosure legislation, and how many are turning to third parties to do the job.

Sales reps faced another round of layoffs last week as Sanofi-Aventis restructures its sales force due to looming generic competition and a dip in sales.

HBA Woman of the Year

IMS Health reports a nice increase in prescription sales from 2008 to 2009, even with a recession in full swing. That said, numbers are still well below the historic sales of a few years back, and it's anyone's guess if they will reach that high again.

Big thinker Bernard Munos delivers the goods.

Dutch pharma releases the same drug as a brand and a generic. Will this two-pronged attack work?

Proving that one good turn deserves another, Pfizer and GlaxoSmithKline announced that they would provide millions of doses of pneumonia vaccines to some of the world's most impoverished countries at massive discounts.

The number of consumers ditching their drugs at the pharmacy keeps climbing as the economy worsens.

A new report from IMS Health bumps the number of emerging markets to 17 and predicts that these nations will account for $90 billion in sales in the next four years. How will pharma take advantage of the opportunity?

NCM - Bold Brands Drive Revenue with Storytelling